Related Experiment Video

Updated: Feb 16, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.2K

Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials

Masatoshi Kudo1, Tadaaki Arizumi

  • 1Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Oncology
|December 20, 2017
PubMed

Insights

Sorafenib is an oral targeted therapy for advanced liver cancer (HCC). This review examines clinical trials combining transarterial chemoembolization (TACE) with targeted agents for unresectable HCC, noting limited reported outcomes.

Area of Science:

  • Hepatobiliary cancers
  • Medical oncology
  • Interventional radiology

Background:

  • Sorafenib, a multikinase inhibitor, offers prognostic benefit for unresectable hepatocellular carcinoma (HCC).
  • Limitations of sorafenib necessitate development of novel molecular targeted agents.
  • Combination therapies with locoregional treatments are under investigation for advanced HCC.

Purpose of the Study:

  • To review clinical trials evaluating molecular targeted agents combined with transarterial chemoembolization (TACE) in unresectable HCC.
  • To assess the reported treatment outcomes of TACE combined with molecular targeted agents.

Main Methods:

  • Systematic review of published clinical trials.
  • Focus on studies involving unresectable HCC patients treated with TACE and molecular targeted agents.
  • Analysis of reported efficacy and safety data.

Main Results:

  • Clinical trials combining TACE with molecular targeted agents for unresectable HCC have not yet reported major treatment outcomes.
  • Limited data exists on the efficacy and safety of these combination therapies.

Conclusions:

  • Further research and well-designed clinical trials are needed to establish the role of TACE combined with molecular targeted agents in unresectable HCC.
  • Identifying optimal combinations and treatment strategies remains a critical unmet need.
Keywords:
BrivanibClinical trialHepatocellular carcinomaMolecular targeted agentOrantinibSorafenibTransarterial chemoembolization

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K